Treatment of osteoarthritis with aspartame

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 5, 1998, Pages 580-593

  Edmundson, Allen B ^a   Manion, Carl V ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTAME; BENCE JONES PROTEIN; TURPENTINE;

ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; BLEEDING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; EPISTAXIS; FEVER; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PAIN ASSESSMENT; PRIORITY JOURNAL; RAT; SINGLE BLIND PROCEDURE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ASPARTAME; BENCE JONES PROTEIN; CRYSTALLOGRAPHY, X-RAY; FEVER; HUMANS; MOLECULAR STRUCTURE; OSTEOARTHRITIS;

EID: 0031862463     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90109-6     Document Type: Article

References (34)

1. Mazur RH, Schlatter JM, Goldkamp AH. Structure-taste relationships of some dipeptides. J Am Chem Soc 1969; 91:2684-91.
2. Schiffman SS, Englehard HH. Taste of dipeptides. Physiol Behav 1976;17:523-35.
3. Mazur RH. Discovery of aspartame. In: Stegink LD, Filer LJ Jr, editors. Aspartame physiology and biochemistry; vol 12. New York: Marcel Dekker; 1984. p. 3-9.
4. Matsuzawa Y, O'Hara Y. Tissue distribution of orally administered isotopically labeled aspartame in the rat. In: Stegink L, Filer LJ Jr, editors. Aspartame physiology and biochemistry. New York: Marcel Dekker; 1984. p. 161-99.
5. Dantzig AH, Hoskins J, Tabas LB, Bright S, Shepard RL, Jenkins IL, et al. Association of intestinal peptide transport with a protein related to the cadherin superfamily. Science 1994;264:430-3.
6. Physician's desk reference. Miacalcin. 51st ed. Montvale (NJ): Medical Economics; 1997.
7. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. Levodopa. In: Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996. p. 509-11.
8. Moore VA, Dunnion DJ, Brown T, Irwin WJ, Akhtar S. Interaction of oligonucleotide conjugates with the dipeptide transporter system in caco-2 cells. Biochem Pharmacol 1997;53:1223-8.
9. Edmundson AB, Ely KR, Abola EE, Schiffer M, Panagiotopoulos N. Rotational allomerism and divergent evolution of domains in immunoglobulin light chains. Biochemistry 1975;14:3953-61.
10. Ely KR, Herron JN, Harker M, Edmundson AB. Three-dimensional structure of a light chain dimer crystallized in water; conformational flexibility of a molecule in two crystal forms. J Mol Biol 1989;210:601-15.
11. Edmundson AB, Ely KR, Herron JN. A search for sitefilling ligands in the Meg Bence-Jones dimer: crystal binding studies of fluorescent compounds. Mol Immunol 1984;21:561-76.
12. Edmundson AB, Ely KR. Binding of N-formylated chemotactic peptides in crystals of the Meg light chain dimer: similarities with neutrophil receptors. Mol Immunol 1985;22:463-75.
13. Edmundson AB, Ely KR, Herron JN, Cheson BD. The binding of opioid peptides to the Mcg light chain dimer: flexible keys and adjustable locks. Mol Immunol 1987; 24:915-35.
14. Edmundson AB, Harris DL, Fan ZC, Guddat LW, Schley BT, Hanson BL, et al. Principles and pitfalls in designing site-directed peptide ligands. Proteins 1993; 16:246-67.
15. Edmundson AB, Ely KR, Girling RL, Abola EE, Schiffer M, Westholm FA, et al. Binding of 2,4-dinitrophenyl compounds and other small molecules to a crystalline lambda-type Bence-Jones dimer. Biochemistry 1974;13: 3816-27.
16. Brünger AT. X-PLOR version 3.1: a system for x-ray crystallography and NMR. New Haven (CT): Yale University Press; 1992.
17. Motulsky H. Prism biostatistics program. 2.01 ed. San Diego: GraphPad Software; 1996.
18. Mielke CH Jr, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969;34:204-15.
19. Geysen HM, Rodda SJ, Mason TJ, Tribbick G, Schoofs PG. Strategies for epitope analysis using peptide synthesis. J Immunol Methods 1987;102:259-74.
20. Tribbick G, Edmundson AB, Mason TJ, Geysen HM. Similar binding properties of peptide ligands for a human immunoglobulin and its light chain dimer. Mol Immunol 1989;26:625-35.
21. Thomas KA, Smith GM, Thomas TB, Feldman RJ. Electronic distributions within protein phenylalanine aromatic rings are reflected by the three-dimensional oxygen atom environments. Proc Natl Acad Sci USA 1982;79:4843-7.
22. Anchin JM, Linthicum DS. Molecular and computational techniques for modelling antibody combining sites. J Clin Immunoassay 1992;15:35-41.
23. Guddat LW, Shan L, Anchin JM, Linthicum DS, Edmundson AB. Local and transmitted conformational changes on complexation of an anti-sweetener Fab. J Mol Biol 1994;236:247-74.
24. Guddat LW, Shan L, Fan ZC, Andersen KN, Rosauer R, Linthicum DS, et al. Intramolecular signaling upon complexation. FASEB J 1995;9:101-6.
25. Fan ZC, Shan L, Guddat LW, He XM, Gray WR, Raison RL, et al. Three-dimensional structure of an Fv from a human IgM immunoglobulin. J Mol Biol 1992;228:188-207.
26. Faber C, Shan L, Fan ZC, Guddat LW, Furebring C, Ohlin M, et al. Three-dimensional structure of a human Fab with high affinity for tetanus toxoid. Immunotechnology 1998;3:253-70.
27. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
28. Moreland LW, Baumgartner SW, Schiff MH, Tindell EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
29. Picot D, Loll PJ, Garavito RM. The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994;367:243-9.
30. Ely KR, Girling RL, Schiffer M, Cunningham DE, Edmundson AB. Preparation and properties of crystals of a Bence-Jones dimer with mercury inserted into the interchain disulfide bond. Biochemistry 1973;12: 4233-7.
31. Scandinavian simvastatin survival study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study. Lancet 1994;344:1338-9.
32. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol. Cholesterol and Recurrent Events Trial investigators [see comments]. N Engl J Med 1996;335:1001-9.
33. Koradi R, Billeter M, Wuthrich K. MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph 1996;14:51-5.
34. POV-Ray Team. Persistence of Vision Ray Tracer. 1996. Available from POV-Ray Team, C. Young, coordinator, 3119 Cossell Dr., Indianapolis, IN 46224.